Stelis Biopharma
-
Syngene to acquire multi-modal facility from Stelis Biopharma
To add 20,000 litres of installed biologics drug substance manufacturing capacity Syngene announced the acquisition of Unit 3 biologics manufacturing…
Read More » -
Akston Biosciences ends vaccine partnership with Stelis Biopharma
Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine Akston Biosciences Corporation, a…
Read More » -
Mark W Womack joins Stelis Biopharma as CEO
Mark will be stationed at Stelis HQ in Bengaluru, India Stelis Biopharma, a vertically integrated biopharma and vaccines Company and…
Read More » -
Stelis Pharma concludes $195 million series B, C fundraise
Post money valuation for Stelis will be pegged at $350 million Strides Pharma Science said its biotech arm Stelis Biopharma…
Read More » -
RDIF partners with Stelis Biopharma for Sputnik V vaccine
A minimum of 200 million doses of the Russian Sputnik V will be supplied The Russian Direct Investment Fund (RDIF,…
Read More » -
Aditya Puri joins Strides Group as Advisor
He will also be the director of Stelis Biopharma Aditya Puri has joined the Strides Group as an Advisor and…
Read More »